HUE033072T2 - Staphylococcus aureus antigének immunogén készítményei - Google Patents

Staphylococcus aureus antigének immunogén készítményei Download PDF

Info

Publication number
HUE033072T2
HUE033072T2 HUE11804822A HUE11804822A HUE033072T2 HU E033072 T2 HUE033072 T2 HU E033072T2 HU E11804822 A HUE11804822 A HU E11804822A HU E11804822 A HUE11804822 A HU E11804822A HU E033072 T2 HUE033072 T2 HU E033072T2
Authority
HU
Hungary
Prior art keywords
protein
kda
clfa
artificial sequence
polypeptide
Prior art date
Application number
HUE11804822A
Other languages
English (en)
Hungarian (hu)
Inventor
Lakshmi Khandke
Akihisa Nonoyama
Tamara Shafer Hodge
Sandeep Nema
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of HUE033072T2 publication Critical patent/HUE033072T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
HUE11804822A 2010-12-22 2011-12-21 Staphylococcus aureus antigének immunogén készítményei HUE033072T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061426476P 2010-12-22 2010-12-22

Publications (1)

Publication Number Publication Date
HUE033072T2 true HUE033072T2 (hu) 2017-11-28

Family

ID=45444677

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE11804822A HUE033072T2 (hu) 2010-12-22 2011-12-21 Staphylococcus aureus antigének immunogén készítményei
HUE16193095A HUE047263T2 (hu) 2010-12-22 2011-12-21 Staphylococcus aureus antigének stabil immunogén készítményei

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE16193095A HUE047263T2 (hu) 2010-12-22 2011-12-21 Staphylococcus aureus antigének stabil immunogén készítményei

Country Status (18)

Country Link
US (1) US20130259896A1 (cg-RX-API-DMAC7.html)
EP (2) EP2654784B1 (cg-RX-API-DMAC7.html)
JP (1) JP6097478B2 (cg-RX-API-DMAC7.html)
KR (2) KR101808398B1 (cg-RX-API-DMAC7.html)
CN (1) CN103826656B (cg-RX-API-DMAC7.html)
AU (1) AU2011346535B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013016153A2 (cg-RX-API-DMAC7.html)
CA (1) CA2819120C (cg-RX-API-DMAC7.html)
DK (2) DK3150222T3 (cg-RX-API-DMAC7.html)
ES (2) ES2769425T3 (cg-RX-API-DMAC7.html)
HU (2) HUE033072T2 (cg-RX-API-DMAC7.html)
IL (1) IL226793B (cg-RX-API-DMAC7.html)
MX (1) MX350170B (cg-RX-API-DMAC7.html)
PL (2) PL2654784T3 (cg-RX-API-DMAC7.html)
PT (2) PT3150222T (cg-RX-API-DMAC7.html)
RU (1) RU2570730C2 (cg-RX-API-DMAC7.html)
SI (2) SI2654784T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012085872A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2893938B1 (en) 2004-09-22 2019-03-06 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against Staphylococcei
PE20110023A1 (es) 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
MX2012013664A (es) * 2010-06-04 2013-01-24 Wyeth Llc Formulaciones de vacuna.
AU2012266880A1 (en) * 2011-03-16 2013-10-03 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
JP2016540764A (ja) * 2013-12-04 2016-12-28 グリコヴァキシン アーゲー 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防
IL310015B1 (en) * 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
US20170100476A1 (en) * 2014-04-10 2017-04-13 Asit Biotech S.A. Hsp-free allergen preparation
KR20200040812A (ko) * 2017-08-16 2020-04-20 머크 샤프 앤드 돔 코포레이션 폐렴구균 접합체 백신 제제
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
CN112261871B (zh) 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
US20230151102A1 (en) * 2020-01-13 2023-05-18 Aptevo Research And Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
WO1997014800A1 (en) 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
AU1537699A (en) 1997-11-26 1999-06-15 Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency Extracellular matrix-binding proteins from (staphylococcus aureus)
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
MXPA01002119A (es) * 1998-08-31 2003-03-27 Inhibitex Inc Vacunas multicomponentes.
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
BRPI0111639B8 (pt) 2000-06-08 2021-05-25 Intercell Ag uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
JP2004535187A (ja) 2001-06-07 2004-11-25 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
WO2002098369A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
EP2339344A1 (en) 2001-06-15 2011-06-29 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
NZ561879A (en) 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP2893938B1 (en) * 2004-09-22 2019-03-06 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against Staphylococcei
EP2476433A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
EP2086581B1 (en) * 2006-11-07 2014-08-13 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
PE20110023A1 (es) * 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus

Also Published As

Publication number Publication date
CA2819120C (en) 2016-07-05
ES2769425T3 (es) 2020-06-25
PL2654784T3 (pl) 2017-08-31
AU2011346535B2 (en) 2015-09-24
EP3150222B1 (en) 2019-11-27
PT2654784T (pt) 2017-02-13
RU2570730C2 (ru) 2015-12-10
DK3150222T3 (da) 2020-01-27
US20130259896A1 (en) 2013-10-03
JP2012136518A (ja) 2012-07-19
CN103826656B (zh) 2015-08-26
MX2013006960A (es) 2013-07-15
KR101808398B1 (ko) 2017-12-12
ES2614815T3 (es) 2017-06-02
MX350170B (es) 2017-08-28
PL3150222T3 (pl) 2020-05-18
SI3150222T1 (sl) 2020-02-28
WO2012085872A3 (en) 2012-08-30
BR112013016153A2 (pt) 2017-07-11
JP6097478B2 (ja) 2017-03-15
KR20150129071A (ko) 2015-11-18
RU2013128277A (ru) 2015-01-27
EP2654784A2 (en) 2013-10-30
CN103826656A (zh) 2014-05-28
PT3150222T (pt) 2020-02-03
DK2654784T3 (en) 2017-02-13
EP2654784B1 (en) 2016-12-07
WO2012085872A2 (en) 2012-06-28
SI2654784T1 (sl) 2017-01-31
CA2819120A1 (en) 2012-06-28
HUE047263T2 (hu) 2020-04-28
KR20130114210A (ko) 2013-10-16
HK1197370A1 (en) 2015-01-16
EP3150222A1 (en) 2017-04-05
AU2011346535A1 (en) 2013-06-13
IL226793B (en) 2019-02-28

Similar Documents

Publication Publication Date Title
HUE033072T2 (hu) Staphylococcus aureus antigének immunogén készítményei
US9724402B2 (en) Neisseria meningitidis composition and methods thereof
CN1359301B (zh) 含有与Aβ1-10残基内的表位特异性结合的抗体的药物组合物及其应用
ES2728282T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
CN109862908A (zh) 多价肺炎球菌多糖-蛋白质缀合物组合物
HUE026089T2 (hu) NGF elleni antitestek és eljárás alkalmazásukra
HUE027823T2 (hu) Immunstimuláló oligonukleotidok
HU229968B1 (hu) Sztreptokokkusz oltóanyag
Ågren et al. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2-and germinal center-promoting effects
US11472850B2 (en) Neisseria meningitidis composition and methods thereof
CN109890415A (zh) 多价肺炎球菌多糖-蛋白质缀合物组合物
HU230629B1 (hu) Emlős citokin: interleukin-B30 és rokon molekulák
DE69738271T2 (de) Rotavirus-impfstoff
TR201910117T4 (tr) OspA nın mutant fragmanları ve bunlara ilişkin yöntemler ve kullanımları.
BG98426A (bg) Пептиди с органо-защитна активност,метод за тяхното получаване и приложението им за лечение
JP2016516721A (ja) トキソイド、組成物および関連方法
CN109069424A (zh) 脂质体疫苗
AT503297B1 (de) Allergen-spezifische antikörper
Felix et al. The preparation of anti-typhoid serum in the horse for therapeutic use in man
DE60125959T2 (de) Unterscheidung zwischen gnrh-i und gnrh-ii
CN114555629A (zh) 糖肽疫苗
Silva et al. Caries vaccine: current reality or remote future
BR102018005192A2 (pt) Globulina imune, método para preparar uma globulina imune, método para tratar infecção, método para fornecer imunoterapia e composição de plasma agrupado
Rodrigues An alum particle-based platform to enhance and investigate humoral immune responses to immunization
SA113340369B1 (ar) تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها